Reveal® XT Performance Trial (XPECT)

NCT ID: NCT00680927

Last Updated: 2015-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

247 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-30

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to quantify the accuracy of the atrial fibrillation diagnostics of the Reveal® XT in a clinical setting and to verify overall system performance, R-wave sensing performance, to obtain user feedback, from both patient and physician, and collect data on device safety.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is a prospective, non-randomized, multi-center international post-market study.

The study will be conducted at 20-30 centers primarily in Europe. The study will be conducted at least in Germany, Austria, Switzerland, The Netherlands, and the Czech Republic. Study centers from Canada may also participate, depending on the timelines for regulatory approval and commercial release of the Reveal® XT in this region.

It is expected that between 140 and 200 patients will be enrolled to ensure that at least 47 patients are included to assess the first primary objective and at least 60 patients to assess the second primary objective.

The primary objective is to quantify the AF detection performance of the device.

The patient population will be assessed in two separate cohorts. The first primary objective is to quantify the 24-hour AF burden accuracy in patients with more than 1% AF burden.

The second primary objective is to quantify the detection accuracy of non-arrhythmia in patients with 1% or less AF burden.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Risk of Cardiac Arrhythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

46 hrs Holter ECG recording

Maximum of 2 46 hrs external Holter ECG recordings are required.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient is willing and able to provide his/her informed consent
* Patient has been implanted with a Reveal® XT
* Patient fulfills at least one of the following three additional requirements

1. is scheduled for PV ablation or surgical rhythm control intervention, and the PV ablation or surgical intervention can be deferred until study completion or
2. has documented frequent AF or frequent symptoms attributable to AF or
3. has undergone PV ablation within the last 6 months and still has symptoms attributable to AF

Exclusion Criteria

* Patient has an implanted pacemaker or ICD
* Patient has persistent or permanent AF
* Patient is allergic to adhesive ECG electrodes
* The study will interfere with a therapeutic or diagnostic procedure which is planned or expected during the study period
* Patient is participating in another study that is expected to compromise the results of this study
* Patient is a minor, legally incompetent, or does not meet other local requirements for participation in a clinical study
* Patient is pregnant
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic BRC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Medtronic Bakken Research Center BV

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Guido H. Rieger, MD

Role: STUDY_DIRECTOR

Medtronic Bakken Research Center B.V.

Gerhard Hindricks, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Heart Center Leipzig - University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

LKH - Universitätskliniken

Innsbruck, , Austria

Site Status

A.ö. Krankenhaus der Elisabethinen Linz

Linz, , Austria

Site Status

Salzburger Landeskliniken

Salzburg, , Austria

Site Status

University Gasthuisberg

Leuven, , Belgium

Site Status

Hopital Laval

Québec, , Canada

Site Status

St. Paul's Hospital

Vancouver, , Canada

Site Status

Victoria Cardiac Arrhythmia Trials Inc.

Victoria, , Canada

Site Status

Facultni Nemocnice Brno

Brno, , Czechia

Site Status

Nemocnice Na Homolce Hospital

Prague, , Czechia

Site Status

Klinika Kardiologie IKEM

Prague, , Czechia

Site Status

Herzzentrum Bad Krozingen, Elektrophysiologie

Bad Krozingen, , Germany

Site Status

Kerckhoff Klinik Forschungsgesellschaft

Bad Nauheim, , Germany

Site Status

Charité Campus Mitte

Berlin, , Germany

Site Status

Universitätsklinikum Bonn

Bonn, , Germany

Site Status

Asklepios Klinik St. Georg

Hamburg, , Germany

Site Status

Universität Leipzig Herzzentrum

Leipzig, , Germany

Site Status

Medizinische Universitätsklinik Tübingen

Tübingen, , Germany

Site Status

Medisch Centrum Alkmaar

Alkmaar, , Netherlands

Site Status

Rijnland Ziekenhuis

Leiderdorp, , Netherlands

Site Status

UMC Maastricht

Maastricht, , Netherlands

Site Status

Scientific Research Institute of Circulation Pathology

Novosibirsk, , Russia

Site Status

Almazov Federal Heart, Blood & Endocrinolgoy Centre

Saint Petersburg, , Russia

Site Status

SsUSCH Baska Bystrica

Banská Bystrica, , Slovakia

Site Status

NUSCH Bratislava a.s.

Bratislava, , Slovakia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Austria Belgium Canada Czechia Germany Netherlands Russia Slovakia

References

Explore related publications, articles, or registry entries linked to this study.

Nergardh A, Frick M. Perceived heart rhythm in relation to ECG findings after direct current cardioversion of atrial fibrillation. Heart. 2006 Sep;92(9):1244-7. doi: 10.1136/hrt.2005.082156. Epub 2006 Mar 17.

Reference Type BACKGROUND
PMID: 16547207 (View on PubMed)

Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation. 2005 Jul 19;112(3):307-13. doi: 10.1161/CIRCULATIONAHA.104.518837. Epub 2005 Jul 11.

Reference Type BACKGROUND
PMID: 16009793 (View on PubMed)

Kimman GJ, Theuns DA, Janse PA, Rivero-Ayerza M, Scholten MF, Szili-Torok T, Jordaens LJ. One-year follow-up in a prospective, randomized study comparing radiofrequency and cryoablation of arrhythmias in Koch's triangle: clinical symptoms and event recording. Europace. 2006 Aug;8(8):592-5. doi: 10.1093/europace/eul051. Epub 2006 Jun 27.

Reference Type BACKGROUND
PMID: 16803840 (View on PubMed)

Senatore G, Stabile G, Bertaglia E, Donnici G, De Simone A, Zoppo F, Turco P, Pascotto P, Fazzari M. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2005 Mar 15;45(6):873-6. doi: 10.1016/j.jacc.2004.11.050.

Reference Type BACKGROUND
PMID: 15766823 (View on PubMed)

Patten M, Maas R, Karim A, Muller HW, Simonovsky R, Meinertz T. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol. 2006 Nov;17(11):1216-20. doi: 10.1111/j.1540-8167.2006.00609.x. Epub 2006 Sep 20.

Reference Type BACKGROUND
PMID: 16987384 (View on PubMed)

Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G; Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004 Aug;25(16):1385-94. doi: 10.1016/j.ehj.2004.04.015.

Reference Type BACKGROUND
PMID: 15302102 (View on PubMed)

Kottkamp H, Tanner H, Kobza R, Schirdewahn P, Dorszewski A, Gerds-Li JH, Carbucicchio C, Piorkowski C, Hindricks G. Time courses and quantitative analysis of atrial fibrillation episode number and duration after circular plus linear left atrial lesions: trigger elimination or substrate modification: early or delayed cure? J Am Coll Cardiol. 2004 Aug 18;44(4):869-77. doi: 10.1016/j.jacc.2004.04.049.

Reference Type BACKGROUND
PMID: 15312874 (View on PubMed)

Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol. 2004 Jan 7;43(1):47-52. doi: 10.1016/j.jacc.2003.08.027.

Reference Type BACKGROUND
PMID: 14715182 (View on PubMed)

Strickberger SA, Ip J, Saksena S, Curry K, Bahnson TD, Ziegler PD. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm. 2005 Feb;2(2):125-31. doi: 10.1016/j.hrthm.2004.10.042.

Reference Type BACKGROUND
PMID: 15851283 (View on PubMed)

Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm. 2006 Dec;3(12):1445-52. doi: 10.1016/j.hrthm.2006.07.030. Epub 2006 Aug 3.

Reference Type BACKGROUND
PMID: 17161787 (View on PubMed)

Israel CW, Neubauer H, Olbrich HG, Hartung W, Treusch S, Hohnloser SH; BEATS Study Investigators. Incidence of atrial tachyarrhythmias in pacemaker patients: results from the Balanced Evaluation of Atrial Tachyarrhythmias in Stimulated patients (BEATS) study. Pacing Clin Electrophysiol. 2006 Jun;29(6):582-8. doi: 10.1111/j.1540-8159.2006.00405.x.

Reference Type BACKGROUND
PMID: 16784423 (View on PubMed)

Joshi AK, Kowey PR, Prystowsky EN, Benditt DG, Cannom DS, Pratt CM, McNamara A, Sangrigoli RM. First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. Am J Cardiol. 2005 Apr 1;95(7):878-81. doi: 10.1016/j.amjcard.2004.12.015.

Reference Type BACKGROUND
PMID: 15781022 (View on PubMed)

Vasamreddy CR, Dalal D, Dong J, Cheng A, Spragg D, Lamiy SZ, Meininger G, Henrikson CA, Marine JE, Berger R, Calkins H. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J Cardiovasc Electrophysiol. 2006 Feb;17(2):134-9. doi: 10.1111/j.1540-8167.2006.00359.x.

Reference Type BACKGROUND
PMID: 16533249 (View on PubMed)

Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger G, Purerfellner H; XPECT Trial Investigators. Performance of a new leadless implantable cardiac monitor in detecting and quantifying atrial fibrillation: Results of the XPECT trial. Circ Arrhythm Electrophysiol. 2010 Apr;3(2):141-7. doi: 10.1161/CIRCEP.109.877852. Epub 2010 Feb 16.

Reference Type DERIVED
PMID: 20160169 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMD 446

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

The REACT-ICD Trial
NCT02439424 UNKNOWN PHASE1/PHASE2
SEEQ™ Performance Study
NCT02484898 COMPLETED
REVEAL for Respiration Detection
NCT01956578 UNKNOWN NA
Reveal In-Office Implants
NCT01168427 COMPLETED